OBJECTIVE： To study the pharmacokinetics of triptolide in Tripterygium glycosides tablet in normal rats and adjuvant arthritis model rats in vivo， and provide reference for clinical rational drug use. METHODS： 12 SD rats were randomly divided into normal group and model group， 6 in each group. Model group was subcutaneously injected complete Freund’s adjuvant 0.1 mL to induce adjuvant arthritis model， normal group was subcutaneously injected the same volume of saline. After 14 d modeling， 2 groups were given Tripterygium glycosides tablet suspension 96 mg/kg intragastrically， the blood sample of eyes 0.4 mL were respectively taken before and 10， 30， 45， 60， 90， 120， 150， 180， 240， 300， 420 min after administration. The plasma concentration of triptolide was determined by HPLC， the pharmacokinetic parameters were calculated by DAS 2.0 software， and the parameters were compared. RESULTS： The pharmacokinetic parameters of triptolide in normal group were cmax of （1.139±0.114） μg/mL， tmax of （2.167±0.606） h， t1/2α of （5.500±3.610） h， AUC0-7 h of （5.052±0.371） μg·h/mL， MRT0-7 h of （3.224±0.119） h， and CL of （11.616±2.986） mL/h； and those in model group were cmax of （0.916±0.103） μg/mL， tmax of （3.083±0.801） h， t1/2α of （5.593±1.795） h， AUC0-7 h of （4.707±0.347） μg·h/mL， MRT0-7 h of （3.429±0.139） h， and CL of （11.246±2.638）   mL/h. Compared with normal group， cmax in model group was significantly decreased， tmax and MRT0-7 h were significantly prolonged （P＜0.05）. CONCLUSIONS： Adjuvant arthritis can affect the pharmacokinetics of triptolide in rats in vivo， and promote its absorption and removal.